The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

One in three women diagnosed with MS will subsequently conceive, therefore consideration of the maternal-infant dyad is ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Learn more about whether Alvotech or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Neurologist Stephen Hauser, MD, of the University of California San Francisco, and epidemiology professor Alberto Ascherio, ...

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

Neuro-immunologist Stephen Hauser, MD, whose maverick thinking transformed the treatment landscape for patients with multiple sclerosis (MS), has received the 2025 Breakthrough Prize in Life Sciences.

A new artificial intelligence (AI) tool called MindGlide was found to accurately calculate MS-related brain damage using a ...

Neuro-immunologist Stephen Hauser , MD, whose maverick thinking transformed the treatment landscape for patients with ...